Skip to main content

Advertisement

SpringerLink
Log in

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Allopurinol, the first-line drug for serum urate-lowering therapy in gout, is approved by the US Food and Drug Administration for a dose up to 800 mg/d and is available as a low-cost generic drug. However, the vast majority of allopurinol prescriptions are for doses ≤ 300 mg/d, which often fails to adequately treat hyperuricemia in gout. This situation has been promoted by longstanding, non-evidence-based guidelines for allopurinol use calibrated to renal function (and oxypurinol levels) and designed, without proof of efficacy, to avoid allopurinol hypersensitivity syndrome. Severe allopurinol hypersensitivity reactions are not necessarily dose-dependent and do not always correlate with serum oxypurinol levels. Limiting allopurinol dosing to ≤ 300 mg/d suboptimally controls hyperuricemia and fails to adequately prevent hypersensitivity reactions. However, the long-term safety of elevating allopurinol dosages in chronic kidney disease requires further study. The emergence of novel urate-lowering therapeutic options, such as febuxostat and uricase, makes timely this review of current allopurinol dosing guidelines, safety, and efficacy in gout hyperuricemia therapy, including patients with chronic kidney disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bieber JD, Terkeltaub RA: Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004, 50:2400–2414.

    Article  PubMed  Google Scholar 

  2. Edwards NL: Treatment-failure gout: a moving target. Arthritis Rheum 2008, 58:2587–2590.

    Article  PubMed  Google Scholar 

  3. Sundy JS: Gout management: let’s get it right this time. Arthritis Rheum 2008, 59:1535–1537.

    Article  PubMed  Google Scholar 

  4. Zhang W, Doherty M, Bardin T, et al.: EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312–1324.

    Article  PubMed  CAS  Google Scholar 

  5. Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450–2461.

    Article  PubMed  CAS  Google Scholar 

  6. US National Library of Medicine DailyMed: FDA information: allopurinol tablet. Available at http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=allopurinol. Accessed February 2009.

  7. Jordan KM, Cameron JS, Snaith M, et al.: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007, 46:1372–1374.

    Article  Google Scholar 

  8. Perez-Ruiz F, Hernando I, Villar I, Nolla JM: Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J Clin Rheumatol 2005, 11:129–133.

    Article  PubMed  Google Scholar 

  9. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al.: Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998, 57:545–549.

    Article  PubMed  CAS  Google Scholar 

  10. Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47–56.

    Article  PubMed  CAS  Google Scholar 

  11. Sarawate CA, Brewer KK, Yang W, et al.: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006, 81:925–934.

    Article  PubMed  Google Scholar 

  12. Hare JM, Mangal B, Brown J, et al.: Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008, 51:2301–2309.

    Article  PubMed  CAS  Google Scholar 

  13. Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008, 300:924–932.

    Article  PubMed  CAS  Google Scholar 

  14. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811–1821.

    Article  PubMed  CAS  Google Scholar 

  15. Kiyonobu M, Hisashi Y, Naoyuki K, et al.: Retrospective analysis of liver toxicity due to anti-hyperuricemic drugs in Japan. Gout Nucleic Acid Metabol 2001, 25:21–27.

    Google Scholar 

  16. Tam S, Carroll W: Allopurinol hepatotoxicity. Am J Med 1989, 86:357–358.

    Article  PubMed  CAS  Google Scholar 

  17. Al-Kawas FH, Seeff LB, Berendson RA, et al.: Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med 1981, 95:588–590.

    PubMed  CAS  Google Scholar 

  18. Chawla SK, Patel HD, Parrino GR, et al.: Allopurinol hepatotoxicity. Case report and literature review. Arthritis Rheum 1977, 20:1546–1549.

    Article  PubMed  CAS  Google Scholar 

  19. Lee HY, Ariyasinghe JT, Thirumoorthy T: Allopurinol hypersensitivity syndrome: a preventable severe cutaneous reaction? Singapore Med J 2008, 49:385–387.

    Google Scholar 

  20. Khanna D, Fuldeore MJ, Meissner BL, et al.: The incidence of allopurinol hypersensitivity syndrome: a population perspective. Presented at the Annual American College of Rheumatology Scientific Meeting (ACR/ARHP) Poster Session C. San Francisco, CA; October 23–28, 2008:S672.

  21. Hung SI, Chung WH, Liou LB, et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005, 102:4134–4139.

    Article  PubMed  CAS  Google Scholar 

  22. Lonjou C, Borot N, Sekula P, et al.: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008, 18:99–107.

    Article  PubMed  CAS  Google Scholar 

  23. Dainichi T, Uchi H, Moroi Y, Furue M: Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology 2007, 215:86–88.

    Article  PubMed  Google Scholar 

  24. Emmerson BT, Hazelton RA, Frazer IH: Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum 1988, 31:436–440.

    Article  PubMed  CAS  Google Scholar 

  25. Braden GL, Warzynski MJ, Golightly M, et al.: Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol 1994, 70:145–151.

    Article  PubMed  CAS  Google Scholar 

  26. Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33:1646–1650.

    PubMed  CAS  Google Scholar 

  27. Dalbeth N, Stamp L: Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Sem Dial 2007, 20:391–395.

    Article  Google Scholar 

  28. Vazquez-Mellado J, Morales EM, Tena CP, et al.: Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001, 60:981–989.

    Article  PubMed  CAS  Google Scholar 

  29. Panomvana D, Sripradit S, Angthararak S: Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol 2008, 14:6–11.

    Article  PubMed  Google Scholar 

  30. Perez-Ruiz F, Lioté F: Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007, 57:1324–1328.

    Article  PubMed  Google Scholar 

  31. Perez-Ruiz F, Calabozo M, Herrero-Beites AM, et al.: Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2000, 86:287–291.

    Article  PubMed  CAS  Google Scholar 

  32. Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47:51–59.

    Article  PubMed  CAS  Google Scholar 

  33. Reinders MK, Haagsma C, Jansen TL, et al.: A randomized controlled trial on the efficacy and tolerability with dose-escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis 2008 Jul 16 (Epub ahead of print).

  34. Schumacher HR Jr, Becker MA, Wortmann RL, et al.: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008, 59:1540–1548.

    Article  PubMed  Google Scholar 

  35. Becker M, Schumacher HR Jr, Espinoza L, et al.: A phase 3 randomized, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout [abstract L11]. Presented at the Annual American College of Rheumatology Scientific Meeting Concurrent Session. San Francisco, CA: October 13–28, 2008.

  36. Horiuchi H, Ota M, Nishimura S, et al.: Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice. Life Sci 2000, 66:2051–2070.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, VA Medical Center, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA

    Robert Terkeltaub

Authors
  1. Jeannie Chao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Terkeltaub
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Terkeltaub.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chao, J., Terkeltaub, R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 11, 135–140 (2009). https://doi.org/10.1007/s11926-009-0019-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-009-0019-z

Keywords

Search

Navigation